ReviewDrugs2005
Critical issues in the clinical management of complicated intra-abdominal infections.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02442596 (Abdominal SepsiS Study), which is not on this map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Abdominal SepsiS Study: Epidemiology of Etiology and Outcome
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 178 citations in OpenAlex.
- A Systematic Review of Health-Related Quality-of-Life Measurement in Patients With Complicated Intraabdominal Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Pooled it
- Pooled it
- Minimally Invasive Management of Complicated Diverticular Disease: Current Status and Review of Literature.Digestive diseases and sciences · 2016Pooled it
- Early versus late pre-intensive care unit admission broad spectrum antibiotics for severe sepsis in adults.The Cochrane database of systematic reviews · 2010Pooled it
- Abdominal wound closure in the presence of sepsis: our experience with the use of subcutaneous drain.Ghana medical journal · 2024Trial
- Antibiotic sensitivity in correlation to the origin of secondary peritonitis: a single center analysis.Scientific reports · 2020Trial
- Safety of Metronidazole in Late Pre-term and Term Infants with Complicated Intra-abdominal Infections.The Pediatric infectious disease journal · 2020Trial
- Risk Models of Operative Morbidities in 16,930 Critically Ill Surgical Patients Based on a Japanese Nationwide Database.Medicine · 2015Trial
- Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia.Digestive diseases and sciences · 2014Trial
- Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.Surgical infections · 2014Trial
- Candida albicans activates Staphylococcus aureus virulence regulatory systems to drive toxin-mediated human cell death.PLoS pathogens · 2026Article
- Article
- Diagnostic utility of IL-18 plasma levels in distinguishing abdominal from non-abdominal sepsis.Frontiers in immunology · 2025Article
- Article
- Predicting surgical outcomes of acute diffuse peritonitis: Updated risk models based on real-world clinical data.Annals of gastroenterological surgery · 2024Article
- Antimicrobial De-Escalation in Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2024Review
- Farnesol remodels the peritoneal cavity immune environment influencingInfection and immunity · 2023Article
- Optimized Treatment of Nosocomial Peritonitis.Antibiotics (Basel, Switzerland) · 2023Review
- Updates on the Causes, Diagnosis, and Management of Peritoneal Abscesses: A Systematic Review.Cureus · 2023Review
- A double-blinded randomized placebo-controlled non-inferiority trial protocol for postoperative infections associated with canine pyometra.BMC veterinary research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra-abdominal infections differ from other infections through the broad variety in causes and severity of the infection, the aetiology of which is often polymicrobial, the microbiological results that are difficult to interpret and the essential role of surgical intervention. From a clinical viewpoint, two major types of intra-abdominal infections can be distinguished: uncomplicated and complicated. In uncomplicated intra-abdominal infection, the infectious process only involves a single organ and no anatomical disruption is present. Generally, patients with such infections can be managed with surgical resection alone and no antimicrobial therapy besides perioperative prophylaxis is necessary. In complicated intra-abdominal infections, the infectious process proceeds beyond the organ that is the source of the infection, and causes either localised peritonitis, also referred to as abdominal abscess, or diffuse peritonitis, depending on the ability of the host to contain the process within a part of the abdominal cavity. In particular, complicated intra-abdominal infections are an important cause of morbidity and are more frequently associated with a poor prognosis. However, an early clinical diagnosis, followed by adequate source control to stop ongoing contamination and restore anatomical structures and physiological function, as well as prompt initiation of appropriate empirical therapy, can limit the associated mortality. The biggest challenge with complicated intra-abdominal infections is early recognition of the problem. Antimicrobial management is generally standardised and many regimens, either with monotherapy or combination therapy, have proven their efficacy. Routine coverage against enterococci is not recommended, but can be useful in particular clinical conditions such as the presence of septic shock in patients previously receiving prolonged treatment with cephalosporins, immunosuppressed patients at risk for bacteraemia, the presence of prosthetic heart valves and recurrent intra-abdominal infection accompanied by severe sepsis. In patients with prolonged hospital stay and antibacterial therapy, the likelihood of involvement of antibacterial-resistant pathogens must be taken into account. Antimicrobial coverage of Candida spp. is recommended when there is evidence of candidal involvement or in patients with specific risk factors for invasive candidiasis such as immunodeficiency and prolonged antibacterial exposure. In general, antimicrobial therapy should be continued for 5-7 days. If sepsis is still present after 1 week, a diagnostic work up should be performed, and if necessary a surgical reintervention should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.